Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.